What is the agreement between Novo Nordisk and Hims & Hers?

Novo Nordisk will partner with Hims & Hers to sell its approved Ozempic and Wegovy drugs on the Hims & Hers platform, resolving a legal dispute over compounded versions of these GLP-1 medications.

Will Hims & Hers still offer compounded GLP-1 drugs?

Hims & Hers will stop advertising compounded GLP-1 drugs but will continue to offer them when providers deem it clinically necessary, adhering to FDA regulations.

How does the partnership affect the price of Ozempic and Wegovy?

Hims & Hers will offer approved Ozempic and Wegovy at Novo Nordisk's self-pay prices, making them comparable to compounded versions and accessible to consumers.

Home / Business and Economy / Ozempic Maker Settles Lawsuit With Hims & Hers

Ozempic Maker Settles Lawsuit With Hims & Hers

10 Mar

•

Summary

Novo Nordisk to sell Ozempic and Wegovy via Hims & Hers.
Partnership resolves lawsuit over compounded GLP-1 drugs.
Hims will now offer FDA-approved injectables at Novo's prices.

Ozempic Maker Settles Lawsuit With Hims & Hers

Novo Nordisk announced on Monday a new partnership with Hims & Hers, allowing the telehealth company to sell the blockbuster drugs Ozempic and Wegovy. This agreement concludes a legal battle that began when Novo Nordisk sued Hims in February over compounded versions of its GLP-1 medications.

Hims will now offer FDA-approved Ozempic and Wegovy injectables, along with the Wegovy pill, on its platform. These will be sold at Novo's self-pay prices, making them competitive with compounded alternatives. The company stated that compounded GLP-1 drugs will continue to be offered only when deemed clinically necessary by providers, aligning with FDA regulations.